BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27512952)

  • 1. Glial degeneration with oxidative damage drives neuronal demise in MPSII disease.
    Zalfa C; Verpelli C; D'Avanzo F; Tomanin R; Vicidomini C; Cajola L; Manara R; Sala C; Scarpa M; Vescovi AL; De Filippis L
    Cell Death Dis; 2016 Aug; 7(8):e2331. PubMed ID: 27512952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved.
    Fusar Poli E; Zalfa C; D'Avanzo F; Tomanin R; Carlessi L; Bossi M; Nodari LR; Binda E; Marmiroli P; Scarpa M; Delia D; Vescovi AL; De Filippis L
    Cell Death Dis; 2013 Nov; 4(11):e906. PubMed ID: 24201805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
    Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
    J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
    Rigon L; Salvalaio M; Pederzoli F; Legnini E; Duskey JT; D'Avanzo F; De Filippis C; Ruozi B; Marin O; Vandelli MA; Ottonelli I; Scarpa M; Tosi G; Tomanin R
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.
    Polito VA; Abbondante S; Polishchuk RS; Nusco E; Salvia R; Cosma MP
    Hum Mol Genet; 2010 Dec; 19(24):4871-85. PubMed ID: 20876612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).
    Bellesso S; Salvalaio M; Lualdi S; Tognon E; Costa R; Braghetta P; Giraudo C; Stramare R; Rigon L; Filocamo M; Tomanin R; Moro E
    Hum Mol Genet; 2018 Jul; 27(13):2262-2275. PubMed ID: 29648648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).
    Motas S; Haurigot V; Garcia M; Marcó S; Ribera A; Roca C; Sánchez X; Sánchez V; Molas M; Bertolin J; Maggioni L; León X; Ruberte J; Bosch F
    JCI Insight; 2016 Jun; 1(9):e86696. PubMed ID: 27699273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice.
    Polito VA; Cosma MP
    Am J Hum Genet; 2009 Aug; 85(2):296-301. PubMed ID: 19679226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
    Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
    Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy.
    Ellison S; Liao A; Gleitz HFE; Parker H; Booth L; Robinson J; Wood S; Taylor J; Holley R; Bigger BW
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101127. PubMed ID: 37920237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease.
    Mandolfo O; Liao A; Singh E; O'leary C; Holley RJ; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):243-255. PubMed ID: 37427450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.
    Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W
    Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular analysis of IDS gene and prenatal diagnosis in a Chinese family with mucopolysaccharidosis type II].
    Jia B; Xue JJ; Liang DS; Wu LQ
    Zhonghua Er Ke Za Zhi; 2009 Feb; 47(2):109-13. PubMed ID: 19573456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
    Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
    Singh S; Mishra A; Shukla S
    Mol Neurobiol; 2016 Sep; 53(7):4286-301. PubMed ID: 26223802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
    Horgan C; Jones SA; Bigger BW; Wynn R
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS).
    Friso A; Tomanin R; Zanetti A; Mennuni C; Calvaruso F; La Monica N; Marin O; Zacchello F; Scarpa M
    Biochim Biophys Acta; 2008 Oct; 1782(10):574-80. PubMed ID: 18675343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucopolysaccharidosis type II in a female carrying a heterozygous stop mutation of the iduronate-2-sulfatase gene and showing a skewed X chromosome inactivation.
    Piña-Aguilar RE; Zaragoza-Arévalo GR; Rau I; Gal A; Alcántara-Ortigoza MA; López-Martínez MS; Santillán-Hernández Y
    Eur J Med Genet; 2013 Mar; 56(3):159-62. PubMed ID: 23232253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro.
    Daniele A; Tomanin R; Villani GR; Zacchello F; Scarpa M; Di Natale P
    Biochim Biophys Acta; 2002 Dec; 1588(3):203-9. PubMed ID: 12393174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: New mutations in the iduronate-2-sulfatase (IDS) gene.
    Filocamo M; Bonuccelli G; Corsolini F; Mazzotti R; Cusano R; Gatti R
    Hum Mutat; 2001 Aug; 18(2):164-5. PubMed ID: 11462244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.